Aclaris Therapeutics Stock Price To Earnings To Growth

ACRS Stock

USD 3.82 0.19 5.23%

Aclaris Therapeutics fundamentals help investors to digest information that contributes to Aclaris Therapeutics' financial success or failures. It also enables traders to predict the movement of Aclaris Stock. The fundamental analysis module provides a way to measure Aclaris Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aclaris Therapeutics stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Aclaris Therapeutics Company Price To Earnings To Growth Analysis

Aclaris Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

Current Aclaris Therapeutics Price To Earnings To Growth

(0.13) X

Most of Aclaris Therapeutics' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aclaris Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Aclaris Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for Aclaris Therapeutics is extremely important. It helps to project a fair market value of Aclaris Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Aclaris Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aclaris Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aclaris Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Property Plant Equipment	Net Tangible Assets	Deferred Long Term Liab	Long Term Investments	Net Receivables	Capital Surpluse	Common Stock	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Long Term Debt Total	Current Deferred Revenue
Total Assets		0.99	-0.48	-0.62	0.86	0.94	0.51	0.97	0.28	0.97	0.59	0.49	0.52	0.73	0.82	0.02	-0.19	-0.01	0.5	-0.33	0.46
Total Stockholder Equity	0.99		-0.53	-0.56	0.79	0.95	0.36	0.98	0.26	0.98	0.51	0.5	0.47	0.67	0.81	0.04	-0.18	0.01	0.42	-0.27	0.42
Net Debt	-0.48	-0.53		0.13	-0.34	-0.58	0.07	-0.52	-0.26	-0.48	-0.05	-0.14	-0.03	-0.21	-0.46	0.04	0.03	0.02	0.0	0.02	-0.03
Retained Earnings	-0.62	-0.56	0.13		-0.73	-0.52	-0.62	-0.57	-0.42	-0.63	-0.8	-0.64	-0.14	-0.94	-0.78	0.61	0.58	0.55	-0.72	0.87	-0.69
Accounts Payable	0.86	0.79	-0.34	-0.73		0.7	0.72	0.77	0.61	0.77	0.9	0.3	0.68	0.8	0.84	-0.29	-0.19	-0.36	0.63	-0.57	0.4
Short Term Investments	0.94	0.95	-0.58	-0.52	0.7		0.35	0.98	0.18	0.91	0.38	0.44	0.29	0.63	0.73	0.08	-0.11	0.15	0.49	-0.27	0.4
Total Liab	0.51	0.36	0.07	-0.62	0.72	0.35		0.39	0.19	0.36	0.71	0.12	0.53	0.67	0.44	-0.12	-0.14	-0.14	0.69	-0.44	0.45
Total Current Assets	0.97	0.98	-0.52	-0.57	0.77	0.98	0.39		0.25	0.95	0.48	0.48	0.38	0.67	0.8	0.03	-0.15	0.07	0.5	-0.32	0.43
Property Plant Equipment	0.28	0.26	-0.26	-0.42	0.61	0.18	0.19	0.25		0.24	0.7	-0.01	0.28	0.36	0.56	-0.63	-0.07	-0.64	0.29	-0.66	-0.02
Net Tangible Assets	0.97	0.98	-0.48	-0.63	0.77	0.91	0.36	0.95	0.24		0.53	0.62	0.39	0.75	0.81	-0.01	-0.28	-0.06	0.4	-0.34	0.55
Deferred Long Term Liab	0.59	0.51	-0.05	-0.8	0.9	0.38	0.71	0.48	0.7	0.53		0.22	0.58	0.8	0.75	-0.58	-0.22	-0.64	0.7	-0.77	0.39
Long Term Investments	0.49	0.5	-0.14	-0.64	0.3	0.44	0.12	0.48	-0.01	0.62	0.22		-0.14	0.57	0.52	-0.17	-0.81	-0.21	0.09	-0.4	0.6
Net Receivables	0.52	0.47	-0.03	-0.14	0.68	0.29	0.53	0.38	0.28	0.39	0.58	-0.14		0.23	0.41	0.09	0.1	-0.15	0.23	0.05	-0.09
Capital Surpluse	0.73	0.67	-0.21	-0.94	0.8	0.63	0.67	0.67	0.36	0.75	0.8	0.57	0.23		0.79	-0.44	-0.37	-0.41	0.74	-0.78	0.77
Common Stock	0.82	0.81	-0.46	-0.78	0.84	0.73	0.44	0.8	0.56	0.81	0.75	0.52	0.41	0.79		-0.49	-0.3	-0.49	0.6	-0.65	0.37
Net Invested Capital	0.02	0.04	0.04	0.61	-0.29	0.08	-0.12	0.03	-0.63	-0.01	-0.58	-0.17	0.09	-0.44	-0.49		0.32	0.92	-0.47	0.83	-0.09
Short Long Term Debt	-0.19	-0.18	0.03	0.58	-0.19	-0.11	-0.14	-0.15	-0.07	-0.28	-0.22	-0.81	0.1	-0.37	-0.3	0.32		0.38	0.05	0.38	-0.45
Net Working Capital	-0.01	0.01	0.02	0.55	-0.36	0.15	-0.14	0.07	-0.64	-0.06	-0.64	-0.21	-0.15	-0.41	-0.49	0.92	0.38		-0.3	0.7	-0.05
Short Term Debt	0.5	0.42	0.0	-0.72	0.63	0.49	0.69	0.5	0.29	0.4	0.7	0.09	0.23	0.74	0.6	-0.47	0.05	-0.3		-0.7	0.33
Long Term Debt Total	-0.33	-0.27	0.02	0.87	-0.57	-0.27	-0.44	-0.32	-0.66	-0.34	-0.77	-0.4	0.05	-0.78	-0.65	0.83	0.38	0.7	-0.7		-0.48
Current Deferred Revenue	0.46	0.42	-0.03	-0.69	0.4	0.4	0.45	0.43	-0.02	0.55	0.39	0.6	-0.09	0.77	0.37	-0.09	-0.45	-0.05	0.33	-0.48

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict Aclaris Therapeutics

Aclaris Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

0.13

At this time, Aclaris Therapeutics' Price Earnings To Growth Ratio is comparatively stable compared to the past year.

Based on the latest financial disclosure, Aclaris Therapeutics has a Price To Earnings To Growth of -0.13 times. This is 118.31% lower than that of the Pharmaceuticals sector and 94.37% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 102.66% higher than that of the company.

Aclaris Price To Earnings To Growth Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aclaris Therapeutics' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aclaris Therapeutics could also be used in its relative valuation, which is a method of valuing Aclaris Therapeutics by comparing valuation metrics of similar companies.

Aclaris Therapeutics is currently under evaluation in price to earnings to growth category among its peers.

Aclaris Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Aclaris Therapeutics from analyzing Aclaris Therapeutics' financial statements. These drivers represent accounts that assess Aclaris Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Aclaris Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	78.1M	275.2M	824.9M	73.3M	84.3M	80.1M
Enterprise Value	42.8M	232.4M	798.2M	33.8M	38.9M	37.0M

Aclaris Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aclaris Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aclaris Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Aclaris Fundamentals

	Return On Equity	-0.26
	Return On Asset	-0.19
	Profit Margin	(1.37) %
	Operating Margin	(2.23) %
	Current Valuation	154.19 M
	Shares Outstanding	71.43 M
	Shares Owned By Insiders	3.59 %
	Shares Owned By Institutions	90.20 %
	Number Of Shares Shorted	1.56 M
	Price To Earning	(12.14) X
	Price To Book	2.10 X
	Price To Sales	10.08 X
	Revenue	31.25 M
	Gross Profit	(60.02 M)
	EBITDA	(117.56 M)
	Net Income	(88.48 M)
	Cash And Equivalents	248.6 M
	Cash Per Share	3.73 X
	Total Debt	426 K
	Debt To Equity	0.01 %
	Current Ratio	15.99 X
	Book Value Per Share	1.82 X
	Cash Flow From Operations	(78.33 M)
	Short Ratio	1.43 X
	Earnings Per Share	(0.52) X
	Price To Earnings To Growth	(0.13) X
	Target Price	7.6
	Number Of Employees	86
	Beta	0.12
	Market Capitalization	272.87 M
	Total Asset	197.41 M
	Retained Earnings	(770.8 M)
	Working Capital	97.9 M
	Current Asset	86.52 M
	Current Liabilities	1.55 M
	Net Asset	197.41 M

About Aclaris Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Aclaris Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aclaris Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aclaris Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aclaris Stock Analysis

When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC